Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE8B | O95263 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.35 |
| ▸ | CDK9 | P50750 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320519 | 1.00 | DYRK1A (0.37) | DYRK1APDE1BPDE2APDE8BADORA3 | |
| SCHEMBL16835721 | 0.79 | HPGD (0.36) | PDE4DCHRM4CCNT1CDK9CCNA2 | |
| SCHEMBL760443 | 0.79 | HTR1A (0.35) | CHRM4CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL27031454 | 0.79 | IKBKB (0.37) | DYRK1ACHRM4CCNT1CDK9CCNA2 | |
| SCHEMBL29864280 | 0.79 | HPGD (0.36) | PDE4DCHRM4CCNT1CDK9CCNA2 | |
| SCHEMBL25791509 | 0.76 | CHRNB4 (0.34) | PDE1BPDE2APDE8BADORA3CYP2C19 | |
| SCHEMBL21287272 | 0.76 | KDM4E (0.38) | PDE10AOPRL1 | |
| SCHEMBL29864602 | 0.75 | GRM1 (0.34) | PDE1BPDE2APDE8BADORA3CYP2C19 | |
| SCHEMBL24350922 | 0.74 | CHRM4 (0.51) | CHRM4CHRM2 | |
| SCHEMBL4371506 | 0.73 | DYRK1A (0.38) | DYRK1ACCNT1CDK9CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | DYRK1A 2905/4885PDE1B 1671/4885PDE2A 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.